Feed AVDL
AV
Avadel Pharmaceuticals plc AVDL · NASDAQ
$21.64 +0.00% (+$0.00)
Summary
26 / 100 · Bulios Score
Valuation 0Growth -Profitability 40Quality 15Debt 70Stability 10
What speaks for it
- Out of every 100 USD of revenue, 14 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Revenue (USD)
201820252026
- Analyst estimate
Revenue grew by 23% a year over 5 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Cash and short-term investments $99.9M
Debt $115.8M
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 6
- Sell 0
No analyst has published a price target.
57% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
This revenue breakdown is on the way.
By region
This revenue breakdown is on the way.